Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GV1001: Interim Phase II data

Interim data from the open-label, European Phase II HeptoVax trial in 21 evaluable patients showed no

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE